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the risk of both left atrial (LA) thrombus and 
ischemic stroke.3‑5 Yet, some patients develop LA 
thrombus and experience thromboembolic events 
despite OAC.6‑9 The CHA2DS2‑VASc ‑RAF (conges‑
tive heart failure, hypertension, age ≥75 years, di‑
abetes mellitus, history of stroke or thromboem‑
bolism, vascular disease, age 65 to 74 years, fe‑
male sex, renal dysfunction, type of AF) score has 
been recently proposed to improve LA thrombus 
prediction in AF.9
The aim of the study is to assess the preva‑
lence of LA thrombus in real ‑world patients 
with AF or AFl referred for transesophageal 
echocardiography (TEE),  to identify predictors 
Introduction Since its establishment 25 years 
ago, the “Club 30” of the Polish Cardiac Society 
has gathered young Polish scientists with mean‑
ingful achievements in cardiology.1 The “Club 30” 
Scientific Platform has been created to facilitate 
initiation of and participation in multicenter stud‑
ies among its users, and to promote integration 
of scientific community.2 Multicenter cooperation, 
empowered by the platform, results in an increase 
in the number of enrolled patients and, conse‑
quently, enhances research quality and chances 
for publication in high ‑profile journals.
In patients with atrial fibrillation (AF) and atri‑
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transthoracic echocardiography and Holter mon‑
itoring are also recorded (TABLE 1). If a patient un‑
dergoes repeated TEE during the study (eg, be‑
fore another procedure or a control TEE for LA 
thrombus), this is also reported in the registry 
(separately for a given patient), together with 
data on the current antithrombotic treatment.
The primary endpoint of the study is the pres‑
ence of LA thrombus on TEE.
The study was approved by the Ethics Com‑
mittee of the Medical University of Warsaw 
(AKBE/113/2018). The Ethics Committee waived 
the requirement of obtaining informed consent 
from the patients.
Statistical analysis The proportion of patients 
undergoing ablation to those undergoing cardio‑
version, as well as patients’ clinical characteris‑
tics and thromboembolic risk, may vary between 
participating centers depending on their individu‑
al profiles. Still, it may be anticipated that approx‑
imately 85% to 90% of enrolled patients will re‑
ceive OAC. In OAC ‑treated populations, the preva‑
lence of LA thrombus ranges from 1% to 10%.8‑12 If 
the registry includes a total of 2600 patients, over 
100 cases of LA thrombus are anticipated, pro‑
viding an adequate number of study endpoints 
for a logistic regression analysis of the predictors 
of LA thrombus. Receiver operating character‑
istic curves will be constructed and areas under 
the curve calculated to assess the prognostic ac‑
curacy of the CHA2DS2‑VASc ‑RAF score (in com‑
parison with other models) for the identification 
of LA thrombus in these patients, and to validate 
the CHA2DS2‑VASc ‑RAF score.
Methods The LATTEE registry (Left Atrial 
Thrombus on Transesophageal Echocardiogra‑
phy; ClinicalTrials.gov identifier, NCT03591627) 
is an ongoing multicenter prospective observa‑
tional study, conducted in 13 Polish cardiology cen‑
ters. The registry includes all consecutive patients 
with AF or AFl hospitalized in a participating cen‑
ter during the study period, who were scheduled 
for catheter ablation or cardioversion for AF or 
AFl and had TEE performed prior to the proce‑
dure (irrespective of whether the procedure was 
finally carried out or not). The exclusion criteria 
are age below 18 years and inconclusive TEE re‑
sults regarding the presence of LA thrombus. Pa‑
tients are enrolled in the study irrespective of 
the presence or type of OAC. Each of the 13 par‑
ticipating centers will include at least 200 patients. 
Thus, the total number of patients in the registry 
is estimated to exceed 2600. In each participating 
center, recruitment will last 12 months, starting 
from the date of enrollment of the first patient 
in this center, or longer if the required number 
of 200 patients is not reached by the participat‑
ing center within 12 months.
In all patients, data on clinical character‑
istics, pharmacotherapy, routine blood tests, 
and TEE results are collected. All other tests 
are performed at the di scretion of the attend‑
ing physician within the standards of care in 
a given center. However, if available, data from 
Table 1 Laboratory data collected in the LATTEE registry
Test Data
In all patients
Blood tests Complete blood count
Creatinine, GFR
Alanine and aspartate aminotransferases
INR, APTT
TEE Presence of LA thrombus
Location of LA thrombus (LAA vs LA cavity)
Presence of SEC, including dense SEC
LAA emptying velocity (in relation to rhythm during TEE)
If available
TEE LAA morphology (windsock, chicken wing, cactus, or cauliflower)




Holter monitoring Presence of AF or AFl
AF or AFl burden
Abbreviations: AF, atrial fibrillation; AFl, atrial flutter; APTT, activated partial thromboplastin time; Ap2Ch, apical 2‑chamber view; 
Ap4Ch, apical 4‑chamber view; GFR, glomerular filtration rate; INR, international normalized ratio; LA, left atrial; LAA, left atrial 
appendage; LAVI, left atrial volume index; PLAX, parasternal long ‑axis view; SEC, spontaneous echo contrast; TEE, transesophageal 
echocardiography
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LA thrombus in patients treated with OAC and in 
different AF subpopulations. A significant num‑
ber of centers participating in the LATTEE reg‑
istry proves the utility of the “Club 30” Scientif‑
ic Platform and reflects the will for integration 
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of patients with LA thrombus. Analyses will be 
performed using the SAS software, version 9.2 
(SAS Institute, Cary, North Carolina, United States).
Discussion The CHA2DS2‑VASc score is a rec‑
ommended tool for thromboembolic risk strati‑
fication in AF and AFl.3 Still, it may not encom‑
pass all clinically relevant predictors of LA throm‑
bus formation.6,7,13‑15 The type of AF has long been 
perceived as irrelevant for thromboembolic risk 
assessment. However, recently, nonparoxysmal 
AF has been shown to be independently associated 
with a higher risk of thromboembolic events than 
paroxysmal AF.6,7,9 Moreover, in paroxysmal AF, 
evaluation of AF burden might improve throm‑
boembolic risk stratification.14 Renal dysfunction 
is another variable found to be a strong predictor 
of stroke and systemic embolism that is not in‑
cluded in the CHA2DS2‑VASc score.
15 
Recently, a new CHA2DS2‑VASc–based model, 
namely, the CHA2DS2‑VASc ‑RAF score (R for re‑
nal dysfunction, AF for AF type), has proved su‑
perior to both the CHADS2 and CHA2DS2‑VASc 
scores in identifying patients with LA throm‑
bus.9 The  primary goal of the  LATTEE reg‑
istry is to validate, and possibly recalibrate, 
the CHA2DS2‑VASc ‑RAF score. Secondary anal‑
yses will include evaluation of LA thrombus risk 
in patients on different OAC regimens, depend‑
ing on LA appendage (LAA) morphology, as well 
as in various predefined subgroups, including pa‑
tients with heart failure, aortic stenosis, mitral 
regurgitation, diabetes, chronic kidney disease, 
men vs women, and elderly population.
The main limitation of the LATTEE registry is 
the use of a surrogate endpoint of LA thrombus 
and not ischemic stroke. However, LA thrombo‑
embolism represents the primary mechanism 
involved in the etiopathology of ischemic stroke 
in AF. Thus, we believe that the presence of LA 
thrombus on TEE may be considered an adequate 
surrogate endpoint. Another limitation, result‑
ing from the study methodology (inclusion of pa‑
tients referred for TEE), is that its participants—
scheduled for ablation or cardioversion—can be 
expected to have lower thromboembolic risk than 
the general AF population. However, the identi‑
fication of additional novel risk factors for LAA 
thrombus formation seems to be particularly valu‑
able in patients with presumed low or intermedi‑
ate thromboembolic risk (who will be adequately 
represented in the LATTEE registry) as opposed to 
those who are already known to be at high throm‑
boembolic risk. Finally, it would be ideal to re‑
cord all TEE studies and verify the presence of LA 
thrombus centrally in a core laboratory.  However, 
this has not been undertaken in our registry.
In conclusion, the LATTEE registry is the larg‑
est study of patients with AF or AFl undergoing 
TEE in Poland. It will investigate the prognostic 
accuracy of the CHA2DS2‑VASc ‑RAF score. It will 
also provide information on the residual risk of 
